<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00674102</url>
  </required_header>
  <id_info>
    <org_study_id>CASA404A1101</org_study_id>
    <nct_id>NCT00674102</nct_id>
  </id_info>
  <brief_title>An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The safety, tolerability, efficacy and pharmacokinetics of ASA404 when administered in&#xD;
      combination with paclitaxel and Carboplatin are assessed. ASA404 is administered&#xD;
      intravenously every 21 days to Japanese patients with Non small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety profile and tolerability of ASA404 when administered in combination with paclitaxel and carboplatin in Japanese patients with non small cell lung cancer</measure>
    <time_frame>First cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics profile of ASA404 in Japanese patients</measure>
    <time_frame>every 2 cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>ASA404</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA404</intervention_name>
    <arm_group_label>ASA404</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed non-small cell carcinoma of the lung.&#xD;
&#xD;
          2. Newly diagnosed Stage IIIb disease or Stage IV disease&#xD;
&#xD;
          3. No prior treatment for Stage IIIb/IV non-small cell carcinoma of the lung (Note: Prior&#xD;
             neoadjuvant or adjuvant chemotherapy within 6 months is allowed.)&#xD;
&#xD;
          4. Age ≥ 20 years old&#xD;
&#xD;
          5. WHO Performance status of 0-1&#xD;
&#xD;
          6. Lab values within the range as defined below within 2 weeks of study registration&#xD;
             (Note: without the use of growth factors or blood transfusions):&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt; 2.0 x 109/L&#xD;
&#xD;
               -  Platelets ≥ 100 x109/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9.5 g/dL&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN or 1.5 mg/dL&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT)&#xD;
&#xD;
                  ≤ 2.5 x ULN&#xD;
&#xD;
               -  PT-INR ≤ 1.5 x ULN&#xD;
&#xD;
               -  Potassium ≥ LLN or correctable with supplements.&#xD;
&#xD;
               -  Total calcium (corrected for serum albumin) ≥ LLN or correctable with&#xD;
                  supplements.&#xD;
&#xD;
               -  Magnesium ≥ LLN or correctable with supplements.&#xD;
&#xD;
               -  Females of child-bearing potential must have negative pregnancy test (serum)&#xD;
&#xD;
          7. Life expectancy ≥ 12 weeks&#xD;
&#xD;
          8. Written informed consent obtained according to local guidelines&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Patients having symptomatic CNS metastases and requiring treatment&#xD;
&#xD;
          2. Patients with second primary cancer, with the exception of non-melanoma skin cancer or&#xD;
             cervical cancer in situ.&#xD;
&#xD;
          3. Radiotherapy ≤ 4 weeks prior to registration (In case of palliative radiotherapy 2&#xD;
             weeks prior to registration&#xD;
&#xD;
          4. Major surgery ≤ 4 weeks prior to registration (major surgery is defined by the use of&#xD;
             general anesthesia). Minor surgery ≤ 2 weeks prior to registration. Insertion of a&#xD;
             vascular access device is allowed. Patients must have recovered from all&#xD;
             surgery-related complications.&#xD;
&#xD;
          5. Concurrent use of other investigational agents and patients who have received&#xD;
             investigational agents ≤ 4 weeks prior to registration&#xD;
&#xD;
          6. Prior exposure to VDAs or other vascular targeting agents (anti-VEGF, anti-VEGF&#xD;
             receptor agents, anti-EGFR agents&#xD;
&#xD;
          7. Patients with pleural effusion to be drained (Patients who have recurrence of pleural&#xD;
             effusion and/or it takes 2 weeks before registration after drainage are allowed)&#xD;
&#xD;
          8. Patients with recent hemoptysis associated with NSCLC (&gt;1 teaspoon in a single episode&#xD;
             within 4 weeks)&#xD;
&#xD;
          9. Known allergy or hypersensitivity to platinum-containing drugs, taxanes, other drugs&#xD;
             formulated in Cremophor EL (polyoxyethylated castor oil) or any known excipients of&#xD;
             these drugs.&#xD;
&#xD;
         10. Peripheral sensory neuropathy with functional impairment (CTC Grade 2 neuropathy,&#xD;
             regardless of causality)&#xD;
&#xD;
         11. ≥ CTC Grade 2 cardiac arrhythmias (i.e. symptomatic, but may not require medications).&#xD;
&#xD;
         12. Pregnant or breast feeding females&#xD;
&#xD;
         13. Patients who take medicine that are known to prolong the QT interval&#xD;
&#xD;
         14. Women of child bearing potential or sexually active males, unwilling or unable to use&#xD;
             the required highly effective method(s) of contraception for both sexes while&#xD;
             receiving treatment and for at least 6 months after the discontinuation of study&#xD;
             treatment. (Adequate forms of contraception include IUD, oral or depot contraceptive&#xD;
             or the barrier method plus spermicide.)&#xD;
&#xD;
         15. Patients with any one of the following&#xD;
&#xD;
               -  Patients with Long QT Syndrome&#xD;
&#xD;
               -  Patients with a Baseline 12-lead ECG QTc of &gt; 450 msec in males or &gt; 470 msec in&#xD;
                  females.&#xD;
&#xD;
               -  Congestive heart failure(NY Heart Association class III or IV)&#xD;
&#xD;
               -  Patients with a myocardial infarction within 12 months of study entry&#xD;
&#xD;
               -  Unstable or poorly controlled angina pectoris&#xD;
&#xD;
               -  History of poorly controlled hypertension with anti-hypertensive regimen&#xD;
&#xD;
               -  History of a sustained ventricular tachycardia&#xD;
&#xD;
               -  Any history of ventricular fibrillation or Torsades de Pointes&#xD;
&#xD;
               -  Right bundle branch block and left anterior hemiblock (bifasicular block)&#xD;
&#xD;
               -  Bradycardia defined as heart rate &lt; 50 beat per minutes&#xD;
&#xD;
         16. Concurrent severe and/or uncontrolled medical disease (i.e. uncontrolled diabetes,&#xD;
             chronic renal disease, chronic liver disease, confirmed diagnosis of HIV infection or&#xD;
             active uncontrolled infection).&#xD;
&#xD;
         17. Patients known to be HBV or HCV positive&#xD;
&#xD;
         18. Significant neurological or psychiatric disorder which could compromise participation&#xD;
             in the study&#xD;
&#xD;
         19. Patient unwilling or unable to comply with the protocol&#xD;
&#xD;
         20. Patients who are not adequate to enter the study decided by the investigator from the&#xD;
             medical point of view.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3520</url>
    <description>Results for CASA404A1101 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vascular disrupting agent</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vadimezan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

